Sugi Predict

Sugi Predict / Targets / MGAT3

MGAT3

Beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase · Q09327 · MGAT3 on Sugi Atlas →

495 patent compounds predicted against MGAT3, 254 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL30506358 SCHEMBL30506358 1.00 10/20
SCHEMBL30506361 SCHEMBL30506361 1.00 10/20
SCHEMBL12845600 SCHEMBL12845600 0.54 8/20
SCHEMBL12307497 SCHEMBL12307497 0.44 6/20
SCHEMBL6973354 SCHEMBL6973354 0.49 5/20
SCHEMBL12782863 SCHEMBL12782863 0.48 3/20
SCHEMBL16978181 SCHEMBL16978181 0.48 3/20
SCHEMBL12783443 SCHEMBL12783443 0.47 3/20
SCHEMBL16715439 SCHEMBL16715439 0.42 3/20
SCHEMBL19750110 SCHEMBL19750110 0.50 2/20
SCHEMBL7495325 SCHEMBL7495325 0.49 2/20
SCHEMBL1264391 SCHEMBL1264391 0.49 2/20
SCHEMBL13551623 SCHEMBL13551623 0.47 2/20
SCHEMBL5361704 SCHEMBL5361704 0.42 2/20
SCHEMBL15313750 SCHEMBL15313750 0.41 2/20
SCHEMBL5369910 SCHEMBL5369910 0.41 2/20
SCHEMBL15435319 SCHEMBL15435319 0.40 2/20
SCHEMBL14111931 SCHEMBL14111931 0.39 2/20
SCHEMBL24152344 SCHEMBL24152344 0.39 2/20
SCHEMBL14111938 SCHEMBL14111938 0.38 2/20

Clinical trials — most relevant to MGAT3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Vaccine Treatment for Surgically Resected Pancreatic Cancer PHASE1/PHASE2COMPLETED
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer PHASE1/PHASE2COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes. PHASE2COMPLETED
Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy PHASE2UNKNOWN
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases PHASE1COMPLETED
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy PHASE1COMPLETED
A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia PHASE1WITHDRAWN
Glycosylation in Patients With Galactosaemia nanCOMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease nanRECRUITING
Evaluation of Blood Protein O-GlcNAcylation Levels in Children nanRECRUITING
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease nanRECRUITING
Effect of Migalastat on Cardiac Involvement in Fabry Disease nanCOMPLETED
Risk Factors for the Development of Celiac Disease in Genetically Predisposed Children nanUNKNOWN
The Natural History of Alpha-Mannosidosis nanCOMPLETED
Biomarker for Mannosidosis Disease (BioMannosidosis) nanWITHDRAWN
1,5-AG as a Marker of Postprandial Hyperglycemia and Glucose Variability in Well-controlled Type 2 Diabetes Mellitus nanCOMPLETED
Effect of an Polyphenolic Beverage in Healthy Volunteers nanACTIVE_NOT_RECRUITING
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation nanCOMPLETED
Screening of Fabry Disease in Patients With GI Symptoms nanUNKNOWN
Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption nanUNKNOWN
Evaluation of Blood and Cardiac Protein O-GlcNAcylation Levels in Cardiac Surgery in Children nanRECRUITING
Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors nanNOT_YET_RECRUITING
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) nanWITHDRAWN
Genetic Studies of Lysosomal Storage Disorders nanENROLLING_BY_INVITATION
The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia nanCOMPLETED
Galactose Mediated Glycogen Resynthesis nanCOMPLETED
Accuracy of Hemoglobin A1C to Predict Glycemia in HIV nanCOMPLETED
An MRI Study on Muscular Diseases -Pompe Disease and Dystrophia Myotonica- nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MGAT3 binder may also engage these)

ProteinNameSimilarity
Q10470 — 1.000 Q10470 →
Q02527 — 1.000 Q02527 →
Q5XV99 — 0.996 Q5XV99 →
Q9VLA1 — 0.993 Q9VLA1 →
Q6GX83 — 0.992 Q6GX83 →
Q701R2 — 0.992 Q701R2 →
Q5CB03 — 0.991 Q5CB03 →
E9PVB5 — 0.990 E9PVB5 →
Q5QQ55 — 0.989 Q5QQ55 →
Q92184 — 0.989 Q92184 →
Q02745 — 0.988 Q02745 →
B3H5R0 — 0.988 B3H5R0 →
Q9VPN2 — 0.988 Q9VPN2 →
Q0V9Z3 — 0.988 Q0V9Z3 →
Q80TM9 — 0.988 Q80TM9 →
ST3GAL1 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 0.987 landscape →
P11299 — 0.987 P11299 →
Q6KB59 — 0.987 Q6KB59 →
A0A0F7YYX3 — 0.987 A0A0F7YYX3 →
A2WYE9 — 0.987 A2WYE9 →
Q66624 — 0.987 Q66624 →
Q92183 — 0.987 Q92183 →
Q8BJM7 — 0.987 Q8BJM7 →
H3JU05 — 0.987 H3JU05 →
Q6DE37 — 0.987 Q6DE37 →
Q4G148 — 0.987 Q4G148 →
Q08E15 — 0.987 Q08E15 →
Q10MK2 — 0.987 Q10MK2 →
Q9P2W7 — 0.987 Q9P2W7 →
C7J0P3 — 0.987 C7J0P3 →